Multiple Myeloma and Diabetes-Reference-Cited by-同舟云学术

Multiple Myeloma and Diabetes

Published:2011-11-17 Issue: Volume:2011 Page:1-6
ISSN:2090-4630
Container-title:ISRN Endocrinology
language:en
Short-container-title:ISRN Endocrinology

Author:

Issa Zeinab A.¹,Zantout Mira S.¹,Azar Sami T.¹^ORCID

Affiliation:

1. Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut-Medical Center, 3 Dag Hammarskjold Plaza, 8th floor, New York, NY 10017 , USA

Abstract

Multiple myeloma is a malignant plasma cell disorder that accounts for approximately 10% of all hematologic cancers. It is characterized by accumulation of clonal plasma cells, predominantly in the bone marrow. The prevalence of type 2 diabetes is increasing; therefore, it is expected that there will be an increase in the diagnosis of multiple myeloma with concomitant diabetes mellitus. The treatment of multiple myeloma and diabetes mellitus is multifaceted. The coexistence of the two conditions in a patient forms a major challenge for physicians.

Publisher

Hindawi Limited

Subject

General Economics, Econometrics and Finance

Link

http://downloads.hindawi.com/archive/2011/815013.pdf

Reference59 articles.

1. Clinical Challenges in Caring for Patients With Diabetes and Cancer

2. Multiple Myeloma: Diagnosis and Treatment

3. Treatment of Patients with Myeloma with Comorbid Conditions: Considerations for the Clinician

4. Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer

5. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Strategies and Future Directions in Multiple Myeloma: Disease Overview and Pathophysiology, Conventional Treatments and Emerging Therapies, Challenges and Innovations in Management;European Journal of Medical and Health Research;2024-09-01

2. Multiple myeloma, IL6, and risk of schizophrenia: A Mendelian randomization, transcriptome, and Bayesian colocalization study;eJHaem;2024-04-11

3. Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma;Frontiers in Oncology;2024-03-22

4. Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment;Future Oncology;2022-08

5. Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice: Deliberations and recommendations from an expert panel of hematologists;Journal of Geriatric Oncology;2020-11